The difference in risks of symptomatic ASD were similar across studies (range of risk difference between treatment arms: 1.5%–2.3%), and was only marginally significant for one study at 24 months. 4 At 24 months, one RCT reported a marginally significant decreased risk of symptomatic ASD in the Prestige disc treatment group; 4 however; two additional FDA RCTs using other devices reported no differences in the rates of symptomatic ASD between treatment arms at 24 m
1
—
—